Business context and reporting period
Entity clarification: The supplied filing is TenX Keane Acquisition’s Form 10-Q for the quarter ended September 30, 2023, not a filing by Citius Oncology, Inc. TenX was a SPAC formed to pursue a business combination and had not commenced operating activities. On October 23, 2023, after quarter-end, TenX entered into a merger agreement involving Citius Pharmaceuticals and Citius Oncology.
Financial results and position
- Revenue: No operating revenue in the three or nine months ended September 30, 2023; TenX reported that it would not generate operating revenue before a business combination.
- Net income: Q3 2023 net income was $157,943, versus $0 in Q3 2022. Nine-month 2023 net income was $1,385,964, versus $0 in the comparable 2022 period. Results were driven by trust-account interest, not business operations.
- Costs and margins: General and administrative costs were $421,455 for Q3 and $768,931 for the nine months. Trust investment income was $579,398 and $2,154,895, respectively. Operating losses were $421,455 for Q3 and $768,931 for the nine months. Operating margins are not meaningful because the company had no revenue.
- Cash flow: Nine-month operating cash use was $382,527; investing cash use was $660,000; financing cash provided was $779,875. Cash declined $262,652 to $26,523.
- Liquidity and assets: Total assets were $70,713,071, including $70,627,915 held in the trust account; cash outside the trust was only $26,523. Trust funds were principally intended for a business combination or shareholder redemptions.
- Liabilities and equity: Current liabilities were $1,168,579, including $779,875 due to the sponsor and $383,703 of accrued expenses. Shareholders’ deficit was $1,083,423. No long-term debt obligations were reported; the sponsor advance is due on demand and non-interest-bearing.
Changes versus the prior comparable period
Compared with 2022, TenX reported income and expenses in 2023, reflecting activity after its October 2022 IPO. Nine-month 2023 trust interest income of $2,154,895 more than offset operating expenses. The trust balance increased from $67,813,020 at December 31, 2022 to $70,627,915 at September 30, 2023, including $2,814,895 of remeasurement of redeemable shares. Cash outside the trust fell from $289,175 to $26,523, while current liabilities rose from $31,836 to $1,168,579.
Outlook, risks and unusual items
- Management disclosed substantial doubt about TenX’s ability to continue as a going concern, citing inadequate liquidity outside the trust and the risk of failing to complete a business combination by the deadline. The filing states that failure to complete a combination by January 18, 2024 would require cessation of operations, redemption of public shares, and liquidation.
- On October 18, 2023, TenX deposited $660,000 into the trust to extend its combination deadline to January 18, 2024. The deposit was funded by a non-interest-bearing sponsor note, payable upon completion of a business combination; the sponsor may elect to convert eligible amounts into private units.
- The October 23, 2023 merger agreement with Citius Pharmaceuticals and Citius Oncology is a material subsequent event; the supplied filing does not establish whether or when the transaction will close.
- Public shareholders may redeem shares in connection with a business combination. There is no assurance the transaction will be completed, and a failed combination would lead to liquidation under the stated terms.
- Management reported effective disclosure controls as of September 30, 2023 and no material change in internal control over financial reporting during the quarter. It reported no material litigation and no market or interest-rate risk as of quarter-end.
Important facts for investors to verify
- Confirm the correct issuer: this is TenX Keane Acquisition’s filing, notwithstanding the Citius Oncology request metadata.
- Review the merger agreement, transaction conditions, financing arrangements, expected ownership and dilution, and subsequent closing updates.
- Verify the extension’s terms and status, the January 18, 2024 deadline, and any further extensions or liquidation developments.
- Assess public-share redemption levels and the resulting cash available to the combined company.
- Review the sponsor advance, accrued liabilities, and the company’s limited unrestricted cash and going-concern disclosure.